Single-Dose Epigenetic Shot Cuts LDL Cholesterol for 18 Months in Primate Trials
Scribe Therapeutics launches first human trial of STX-1150, an epigenetic therapy silencing PCSK9 to slash LDL without permanently altering DNA.
Summary
A biotech company called Scribe Therapeutics has received regulatory clearance in Australia to begin human testing of a new cholesterol-lowering treatment called STX-1150. Unlike statins or gene-editing therapies, this approach uses epigenetic silencing — temporarily switching off a gene called PCSK9 that drives LDL cholesterol production — without permanently changing DNA. In primate studies, a single low dose reduced LDL cholesterol by more than 50 percent, and those reductions lasted roughly 18 months. The Phase 1 trial will enroll up to 64 participants across Australia and New Zealand, focusing initially on safety, dosing, and how the body processes the treatment. If human results mirror the animal data, this could eventually offer a long-lasting, non-permanent alternative to daily cholesterol medications.
Detailed Summary
High LDL cholesterol remains one of the most significant and modifiable risk factors for cardiovascular disease, which is the leading cause of death globally. Current options — statins, PCSK9 inhibitor injections, and newer gene-silencing drugs — require either daily pills or regular injections. A durable, single-dose solution would represent a meaningful advance in both convenience and long-term cardiovascular risk management.
Scribe Therapeutics has now received clearance from Australia's Therapeutic Goods Administration to begin a first-in-human Phase 1 trial of STX-1150, its lead investigational therapy. The drug uses the company's proprietary ELXR platform to epigenetically silence the PCSK9 gene in liver cells — reducing the gene's activity without cutting or permanently rewriting the underlying DNA sequence. This distinction matters: reversibility is a potential safety advantage over permanent gene-editing approaches.
The most striking preclinical finding is durability. In non-human primates, a single dose below 1.0 mg per kilogram sustained LDL reductions of greater than 50 percent for approximately 18 months. That magnitude and duration, if reproduced in humans, would rival or exceed current injectable PCSK9 inhibitors, which typically require dosing every two to four weeks.
The Phase 1 trial is open-label, single ascending dose in design, enrolling up to 64 participants across Australian and New Zealand sites, with Monash University's Victorian Heart Hospital as the first site. Primary objectives cover safety, tolerability, pharmacokinetics, and pharmacodynamic effects on LDL cholesterol.
Important caveats apply. Phase 1 trials are primarily safety studies, not efficacy confirmations. Primate data does not guarantee human outcomes. The epigenetic silencing mechanism is novel in humans, and the duration of effect, reversibility, and off-target impacts remain to be characterized. Results are likely years away from clinical availability.
Key Findings
- Single dose of STX-1150 reduced LDL cholesterol by over 50% for ~18 months in non-human primates
- Therapy silences PCSK9 gene epigenetically, avoiding permanent DNA alterations unlike gene-editing approaches
- Phase 1 trial enrolling up to 64 participants in Australia and New Zealand to assess human safety and dosing
- Liver-targeted delivery via ELXR platform aims for sustained effect with low required doses under 1.0 mg/kg
- If effective in humans, could replace frequent statin or PCSK9 inhibitor dosing with a single administration
Methodology
This is a news report summarizing a company press release and regulatory milestone, not a peer-reviewed study. The source, Longevity.Technology, is a credible specialist outlet covering longevity biotech. Evidence basis is preclinical primate data; no human trial results are yet available.
Study Limitations
All efficacy data currently comes from non-human primates; human pharmacodynamics may differ substantially. Phase 1 trials are designed to assess safety, not confirm cholesterol-lowering efficacy in humans. Long-term reversibility of the epigenetic silencing and potential off-target liver effects have not yet been characterized in humans.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.